Mr. Hany Salama
Vice President, Commercial Operations, NEOSTRATA COMPANY, INC.
Member of the Healthcare Council
Council Member Biography
Hany Salama, ME, MBA, CPM, is the Vice President, Commercial Operations at The NeoStrata Company. He has global responsibilities for commercial planning, supply chain, and manufacturing operations for all clinical and marketed products. Mr. Salama is also responsible for all new commercial product launches which include marketing, sales, regulatory, business development, and quality interface. He has over 15 years of chemical and pharmaceutical industry experience with expertise in project management, supply chain management, product launches, and global outsourcing strategies of pharmaceutical APIs and finished product. Mr. Salama is trained in Six Sigma/lean manufacturing operations. He is an Industry Fellow of the Center for Supply Chain Management at Rutgers Business School and a member of the Center's Advisory Board. Mr. Salama is also an Adjunct Professor at William Paterson and Rutgers University, where he teaches Pharma Supply Chain Operations. (This is me - Update Profile)
Employment History
- 2008 - Unspecified
- Vice President, Commercial Operations, NEOSTRATA COMPANY, INC.
- 2006 - 2008
- Director, Global Manufacturing and Pharmaceutical , Barrier Therapeutics, Inc.
- 2002 - 2006
- Associate Director, Global Program Management, HOFFMANN-LA ROCHE INC.
- 2001 - 2002
- Project Engineer, MERCK & CO., INC.
- 1996 - 2001
- Operations Leader, BASF Corporation
GLG NewsSM Analyses by Hany Salama(?)
Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
-
Sterile Injectables Contract Manufacturing Market Outlook
February 28, 2008
Jubilant News for Hollister-Stier | www.contractpharma.com
As demand of the sterile injectables products grows, more and more contract manufacturers are evaluating this landscape as a potential opportunity for growth. The major concerns in this market outlook are how complex is the technology, how much capacity is needed and will this technology be the future for the pharmaceutical and biotech companies and are contract manufacturers ready/capable of the challenges.
-
Sustainable Cost Cutting Efforts Through Strategic Partnerships
January 25, 2008
Pfizer, Novartis, Amgen: cutting costs could boost short-term profits | www.pharmaceutical-business-review.com
In today's ever changing pharmaceutical/biotech landscape, manufacturers need to take an aggressive approach to reduce cost while developing their robust pipelines. To do this successfully, manufacturers need to focus on their core competencies as strategically determined by the senior management of the organization. Companies now need to focus on: 1. Outsourcing of none strategic activities such as manufacturing/packaging, some development activities and clinical operations 2. Look at strategic licensing partnerships to drive more enhanced pipelines 3. Continue to look at the global landscape to leverage effective operational opportunities
Leading institutions connect with Hany Salama through GLG
GLG Study Groups with Hany Salama(?)
| Study Group Name | No. Members |
|---|---|
| Generic Drug Economic Experts | 766 |
| Specialty Chemical Experts | 330 |
| Medical Device Experts | 317 |
| RFID Semiconductor Experts | 279 |
| Radio Frequency Identification Experts | 238 |
GLG Live Meetings with Hany Salama(?)
Hany Salama has not participated in any GLG Live Meetings.